The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.

Background Accurate assessment of neoadjuvant chemotherapy (NAC) response with positron emission tomography/computed tomography (PET/CT) or magnetic resonance imaging (MRI) may provide appropriate operation guidelines for individual breast cancer patients. Purpose To compare the values of PET/CT and MRI for response evaluation following NAC in breast cancer patients. Material and Methods Thirty-three consecutive patients who underwent NAC were included. PET/CT and MRI were performed before and one to four weeks after NAC. With response evaluation of PET/CT and MRI, patients with complete/partial responses on imaging studies were considered to be responders, and those showing stable/progressive disease non-responders. Peak standardized uptake value corrected for lean body mass (SULpeak) and metabolic tumor volume (MTV) were measured from PET/CT, and unidimensional diameter (1D) and tumor volume (TV) from MRI. Reduction rates for each parameter were calculated (Δ%SULpeak, Δ%MTV, Δ%1D, and Δ%TV). The pathological response for NAC as reference was evaluated after surgical resection of the remaining tumor in the breast. Results We identified 17 pathological responders and 16 non-responders. PET/CT had lower specificity and accuracy, but higher sensitivity than MRI, although no significant difference was found between PET/CT and MRI. Following NAC, there were significant differences between pathological responders and non-responders in SULpeak ( P < 0.001), MTV ( P < 0.001), 1D ( P = 0.0003), TV ( P = 0.038), Δ%SULpeak ( P = 0.001), Δ%MTV ( P < 0.001), Δ%1D ( P < 0.001), and Δ%TV ( P = 0.001). Conclusion PET/CT showed lower specificity and accuracy than MRI in evaluating responses to NAC, but both PET/CT and MRI parameters may have predictive value in distinguishing therapeutic responders and non-responders following NAC.